Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etrumadenant Combinations in mCRPC
NCT04381832Phase 2Completed
- Sponsor
- Arcus Biosciences
- Start
- Jul 2020
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of etrumadenant in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Arcus Biosciences. Started Jul 2020; status: completed.
02
Drugs
etrumadenant
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04381832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04381832.